AllSci News
Think Bioscience Raises $55 Million Series A to Advance Rare Disease Drug Discovery Platform
Think Bioscience Secures USD 55 Million to Advance Rare Disease Pipeline Boulder, Colorado-based Thi...
Corvus Pharma Reports Positive Phase 1 Data for ITKi soquelitinib in Atopic Dermatitis
Corvus Pharmaceuticals announced positive data from a Phase 1 trial assessing pipeline candidate soquelitinib as a treatment for moderate to severe atopic…
AstraZeneca Acquires Remaining China Rights to AbelZeta’s GPC3 Armored CAR-T
AstraZeneca agreed to acquire AbelZeta Pharma’s remaining 50% stake in the China development and commercialization rights to C-CAR031, a glypican-3 (GPC3)-targeted armored…
Exciva Raises EUR 51 Million Series B to Advance Groundbreaking Alzheimer's Therapy
Exciva Secures EUR 51 Million to Advance Alzheimer's Therapy Stockholm-based biotech company Exciva ...
Ocugen’s OCU410 modifier gene therapy shows Phase 2 efficacy in geographic atrophy
Ocugen reported positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial of OCU410 (AAV5-RORA), a modifier gene therapy being developed…
STEAP2-Targeted CAR-T Therapy Enters Phase 1 Trial for Metastatic Prostate Cancer
Novel CAR-T Approach Targets Prostate Cancer's Elusive Molecular Landscape Researche...
Brenig Launches First-in-Human Trial of Brain-Selective NLRP3 Inhibitor BT-409
Brenig Therapeutics has initiated the first clinical evaluation of BT-409, a brain-selective small molecule designed to inhibit the NLRP3 inflammasome in neurodegenerative…
Kinaset Therapeutics Raises $103 Million Series B to Advance Inhaled Asthma Drug Therapy
Kinaset Therapeutics Secures USD 103 Million to Advance Inhaled Asthma Therapy Boston-based Kinaset ...
Mediar Therapeutics Raises $76 Million in Series B to Advance Anti-Fibrotic Drug Pipeline
Mediar Therapeutics Secures USD 76 Million to Advance Anti-Fibrotic Pipeline Boston-based Mediar The...
GVV858 Phase 1 Trial: Targeting CCNE1-Amplified Advanced Solid Tumors in Breast and Prostate Cancer
Novel Cancer Therapy GVV858 Enters First-in-Human Trial Targeting Advanced Solid Tumors A first-in-...
J&J’s Tecvayli beats standard of care in early-relapse MM
Johnson & Johnson announced positive Phase 3 data showing that Tecvayli (teclistamab-cqyv) monotherapy significantly improved progression-free survival (PFS) and overall survival (OS)…
DPTX3186 Phase 1 Trial Targets Wnt Pathway in Advanced Solid Tumor Treatment
Novel Wnt Pathway Inhibitor Enters First-in-Human Trial for Solid Tumors Researchers have initiated a first...
Innovent Biologics' IBI3003 Enters First-in-Human Phase I/II Trial for Multiple Myeloma
Novel Multiple Myeloma Therapy Enters First-in-Human Trial Innovent Biologics has initiated a first...
Caldera Launches with USD 112.5m Series A, Puts IL-23p19 / TL1A BsAb into Phase 1
US-based biotech Caldera Therapeutics announced its launch with the finalization of a USD 112.5 million Series A funding round, set to focus…
AstraZeneca’s AZD9750 PROTAC Enters Trials for Metastatic Prostate Cancer
AstraZeneca is initiating a first-in-human clinical trial of AZD9750, a novel androgen receptor (AR) proteolysis targeting chimera (PROTAC), targeting patients with metastatic…
The AllSci Brief
Free, systematic R&D and deal news. Daily.